159 related articles for article (PubMed ID: 33728443)
1. Incidence of skin hyperpigmentation in Black patients receiving treatment with immunomodulatory drugs.
Milrod CJ; Blevins F; Hughes D; Lerner A; Sarosiek S; Sanchorawala V; Sloan JM
Blood; 2021 May; 137(21):2987-2989. PubMed ID: 33728443
[No Abstract] [Full Text] [Related]
2. Lenalidomide-induced cytokine release syndrome in a patient with multiple myeloma.
Nakamura N; Kanemura N; Shibata Y; Matsumoto T; Mabuchi R; Nakamura H; Kitagawa J; Goto N; Hara T; Tsurumi H; Moriwaki H
Leuk Lymphoma; 2014 Jul; 55(7):1691-3. PubMed ID: 24138307
[No Abstract] [Full Text] [Related]
3. New immunomodulatory drugs in myeloma.
Lacy MQ
Curr Hematol Malig Rep; 2011 Jun; 6(2):120-5. PubMed ID: 21327565
[TBL] [Abstract][Full Text] [Related]
4. Lenalidomide desensitization for delayed hypersensitivity reactions in 5 patients with multiple myeloma.
Lee MJ; Wickner P; Fanning L; Schlossman R; Richardson P; Laubach J; Castells M
Br J Haematol; 2014 Oct; 167(1):127-31. PubMed ID: 24824093
[No Abstract] [Full Text] [Related]
5. Acute lymphoblastic leukemia developing during maintenance therapy with lenalidomide in a patient with multiple myeloma.
García-Muñoz R; Robles-de-Castro D; Muñoz-Rodríguez A; Rabasa P
Leuk Lymphoma; 2013 Dec; 54(12):2753-5. PubMed ID: 23488662
[No Abstract] [Full Text] [Related]
6. Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer.
Bennett CL; Angelotta C; Yarnold PR; Evens AM; Zonder JA; Raisch DW; Richardson P
JAMA; 2006 Dec; 296(21):2558-60. PubMed ID: 17148721
[No Abstract] [Full Text] [Related]
7. Outcomes and management of lenalidomide-associated rash in patients with multiple myeloma.
Barley K; He W; Agarwal S; Jagannath S; Chari A
Leuk Lymphoma; 2016 Nov; 57(11):2510-5. PubMed ID: 26943456
[TBL] [Abstract][Full Text] [Related]
8. Pyoderma gangrenosum induced by lenalidomide in a case of multiple myeloma.
Meunier M; Larabi A; Schacherer M; Deteix C; Courby S; Cahn JY
Ann Hematol; 2020 Feb; 99(2):379-380. PubMed ID: 31822948
[No Abstract] [Full Text] [Related]
9. Severe hypocalcemia due to lenalidomide.
Kong S; Collet P; Marotte H; Thomas T
Joint Bone Spine; 2015 Oct; 82(5):380-1. PubMed ID: 25726251
[No Abstract] [Full Text] [Related]
10. Polyclonal immune activation and marrow plasmacytosis in multiple myeloma patients receiving long-term lenalidomide therapy: incidence and prognostic significance.
Zamarin D; Devlin SM; Arcila ME; Landau H; Lesokhin A; Lendvai N; Chung DJ; Chimento D; Weltz J; Babu D; Giralt S; Hassoun H
Leukemia; 2013 Dec; 27(12):2422-4. PubMed ID: 23608883
[No Abstract] [Full Text] [Related]
11. Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents.
Cornell RF; Goldhaber SZ; Engelhardt BG; Moslehi J; Jagasia M; Harrell S; Rubinstein SM; Hall R; Wyatt H; Piazza G
Br J Haematol; 2020 Aug; 190(4):555-561. PubMed ID: 32314352
[TBL] [Abstract][Full Text] [Related]
12. Lenalidomide and the risk of serious infection in patients with multiple myeloma: a systematic review and meta-analysis.
Ying L; YinHui T; Yunliang Z; Sun H
Oncotarget; 2017 Jul; 8(28):46593-46600. PubMed ID: 28423741
[TBL] [Abstract][Full Text] [Related]
13. Thromboembolism with immunomodulatory agents in the treatment of multiple myeloma.
Singh A; Gajra A
Cardiovasc Hematol Agents Med Chem; 2011 Jan; 9(1):7-13. PubMed ID: 20874693
[TBL] [Abstract][Full Text] [Related]
14. Thalidomide and lenalidomide in multiple myeloma.
Mazumder A; Jagannath S
Best Pract Res Clin Haematol; 2006; 19(4):769-80. PubMed ID: 16997182
[TBL] [Abstract][Full Text] [Related]
15. Classical hodgkin lymphoma as de novo B-cell malignancy after treatment of multiple myeloma in the pre-lenalidomide era.
Zago M; Adam P; Goldschmidt H; Fend F; Kanz L; Weisel K
Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):e7-e11. PubMed ID: 24169269
[No Abstract] [Full Text] [Related]
16. B-cell acute lymphoblastic leukemia in an elderly man with plasma cell myeloma and long-term exposure to thalidomide and lenalidomide: a case report and literature review.
Sinit RB; Hwang DG; Vishnu P; Peterson JF; Aboulafia DM
BMC Cancer; 2019 Nov; 19(1):1147. PubMed ID: 31775673
[TBL] [Abstract][Full Text] [Related]
17. The impact of long-term lenalidomide exposure on the cellular composition of bone marrow.
Brioli A; Melchor L; Titley I; Vijayaraghavan G; Stephens C; Zeisig A; Pawlyn C; Cavo M; Morilla R; Davies FE; Morgan GJ
Leuk Lymphoma; 2014 Nov; 55(11):2665-8. PubMed ID: 24660850
[No Abstract] [Full Text] [Related]
18. Potential new risks of lenalidomide.
Gertz MA; Buadi FK
Leuk Lymphoma; 2014 Sep; 55(9):1962-3. PubMed ID: 24304420
[No Abstract] [Full Text] [Related]
19. Thrombosis in multiple myeloma (MM).
Cesarman-Maus G; Braggio E; Fonseca R
Hematology; 2012 Apr; 17 Suppl 1(0 1):S177-80. PubMed ID: 22507814
[TBL] [Abstract][Full Text] [Related]
20. Lung Toxicity after Lenalidomide Treatment in a Patient with Multiple Myeloma.
Cabrera César E; Fernández Aguirre MC; González Fernández A
Arch Bronconeumol; 2017 Jun; 53(6):355-356. PubMed ID: 27939513
[No Abstract] [Full Text] [Related]
[Next] [New Search]
